Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7858789 | ACADIA PHARMS INC | Derivatives of 4-aminopiperidine and their use as a medicament |
Dec, 2020
(3 years ago) | |
US8110574 | ACADIA PHARMS INC | Derivatives of 4-aminopiperidine and their use as a medicament |
Dec, 2020
(3 years ago) | |
US6756393 | ACADIA PHARMS INC | Azacyclic compounds |
Mar, 2021
(3 years ago) | |
US6815458 | ACADIA PHARMS INC | Azacyclic compounds |
Mar, 2021
(3 years ago) | |
US9296694 | ACADIA PHARMS INC | Azacyclic compounds |
Mar, 2021
(3 years ago) | |
US7115634 | ACADIA PHARMS INC | 4-aminopiperidine and their use as a medicine |
Oct, 2021
(2 years ago) | |
US7923564 | ACADIA PHARMS INC | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms |
Sep, 2025
(1 year, 4 months from now) | |
US7732615 | ACADIA PHARMS INC | N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
Jun, 2028
(4 years from now) | |
US7601740 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Apr, 2030
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9765053 | ACADIA PHARMS INC | Methods of treatment using selective 5-HT2A inverse agonists |
Jul, 2022
(1 year, 9 months ago) | |
US8618130 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(3 months ago) | |
US10028944 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(3 months ago) | |
US8921393 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(3 months ago) | |
US9566271 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(3 months ago) | |
US7659285 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Aug, 2026
(2 years from now) | |
US10517860 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(12 years from now) | |
US10953000 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(12 years from now) | |
US11452721 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(14 years from now) | |
US10646480 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(14 years from now) | |
US10449185 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(14 years from now) | |
US10849891 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(14 years from now) |
Nuplazid is owned by Acadia Pharms Inc.
Nuplazid contains Pimavanserin Tartrate.
Nuplazid has a total of 21 drug patents out of which 11 drug patents have expired.
Expired drug patents of Nuplazid are:
Nuplazid was authorised for market use on 28 June, 2018.
Nuplazid is available in capsule;oral, tablet;oral dosage forms.
Nuplazid can be used as treatment of psychosis, treatment of parkinson's disease psychosis, treatment of a neurodegenerative disease or a symptom thereof, treatment of psychosis or a symptom thereof, treatment of hallucinations and delusions associated with parkinson's disease psychosis.
Drug patent challenges can be filed against Nuplazid from 29 April, 2020.
The generics of Nuplazid are possible to be released after 27 August, 2038.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 29, 2021 |
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
NCE-1 date: 29 April, 2020
Market Authorisation Date: 28 June, 2018
Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis; Treatment of psychosis or a symptom thereof; Treatment of a neurodegenerative disease or a symptom thereof; Tre...
Dosage: CAPSULE;ORAL; TABLET;ORAL